A research study on magic mushrooms in Canada revealed that nearly 80% of respondents believe that psilocybin, the primary psychoactive compound in magic mushrooms, should be medically available for distressed patients. Moreover, approximately two-thirds of the Canadian participants concurred that psilocybin should be legally obtainable for those who require it.
Beyond advocating for easier access to the substance, a notable 84.8 percent of participants asserted that the public health system ought to bear the costs of such treatments. Psilocybin is viewed by the majority of Canadians as a credible treatment option, especially for mitigating end-of-life distress.
[toc]
Key Findings:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia recognize psilocybin as a legitimate medical option for addressing end-of-life existential distress.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind studies reported immediate and lasting benefits, with effects persisting for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Such individuals may grapple with feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose in life. This form of distress is particularly prevalent among patients with life-threatening conditions, potentially resulting in a wish for hastened death or suicidal thoughts.
Notably, individuals facing terminal illnesses or significant life changes are the ones most likely to experience this type of distress. It significantly impairs their mental health and overall life quality.
Existential therapy aims to resolve issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, feelings of purposelessness and existential fear. However, it may necessitate numerous sessions and may not yield results for everyone.
The doubt concerning the effectiveness of such therapy is a key reason many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Alternative
Throughout the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in treating complex mental disorders. Psilocybin, notably, has demonstrated a quick and lasting relief of existential distress in patients nearing end-of-life.
Recognizing the possible efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are inadequate, Health Canada revised the Special Access Program in 2022. This revision permits healthcare practitioners to request regulated substances for their patients.
Canadians’ Advocacy for Psilocybin Access
An article published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The article’s data entails:
| Methodology | Engagement from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of them had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical alternative for treating end-of-life existential distress. 63.3% support the inclusion of psilocybin in medical treatments. 84.8% endorse the public health system offering this therapy. 44.2% believe healthcare practitioners should administer the substance without Health Canada’s supervision. |
These findings align with surveys conducted in Canada, England, and Australia. The researchers highlighted the uniqueness of their study as it focuses on using psychoactive substances to alleviate existential distress in end-of-life situations.
Justifications for Canadian Endorsement of Psilocybin Use
There is an increasing acceptance among Canadians of the use of psilocybin as a treatment, primarily due to evidence from esteemed research institutions. The perceived safety of psilocybin mushrooms in reducing existential distress is another contributing factor. Subjects across multiple studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes | |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained | The benefits of the therapy can last up to six months or even longer. Its effectiveness can be attributed to mystical experiences that include a profound sense of unity and deep emotional insights. |
| Trial at New York University | 29 patients were assigned randomly to receive either psilocybin or the active placebo, niacin. | The results were in line with the Johns Hopkins study. Participants who received psilocybin reported a sense of psychological relief, along with an enhanced perspective on life and death. | |
| BMC Palliative Care | Nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The aim of the study was to comprehend the perception of palliative care professionals towards existential distress and their views on psychedelic therapy as a potential treatment option. | Palliative care practitioners suggest that psychedelic-assisted therapy (PAT) might hold potential in alleviating existential distress. |
Patient Experiences
Scientific research isn’t the only source of proof supporting psilocybin’s effectiveness. Numerous patient accounts highlight its potential to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her enlightening experience during her assisted therapy. She visualizes being on a raft, surrounded by nature, and in the company of imaginative creatures. This vision instills in her a profound understanding of the universe’s interconnectedness and support, providing immense peace and affirmation.
Despite undergoing conventional mental health support, Yokoi still faced severe anxiety and distress following her diagnosis. Psilocybin therapy assisted her in reconnecting with her body and experiencing a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working as an administrative supervisor in healthcare at the time of the study and described herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any changes in her religious or spiritual beliefs since her therapy session, she stated that the experiences had infused her beliefs with a sense of purpose and authenticity.
Brenda’s Journey
Throughout her therapy sessions, Brenda had two experiences of near-death. These experiences led her to perceive death as a beautiful phase in the cycle of life rather than something to be feared. According to Brenda, the study initiated her healing process from childhood trauma, a transformation that was reflected in her data. Increased spirituality and reduced anxiety and death fear were observed.
Availability of Psilocybin Products in Canada
At present, the accessibility of psilocybin capsules and other similar products designed for managing existential distress and other mental health conditions can be limited. However, reliable online dispensaries can provide these products when necessary.
| Features | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Descendant of Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; well-suited for beginners. | Also moderately potent; perfect for newcomers. | Extremely potent; advised for users with intermediate to advanced experience. |
| Effects | Generates a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Stimulates an energizing and long-lasting high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal images, and feelings of happiness. | Induces profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood enhancement. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can impose a significant burden on patients nearing the end of their lives. Traditional treatments may not always be effective in dealing with this distress, leading to increasing support in Canada for more accessible magic mushrooms within public healthcare. This growing public interest could
We urge regulatory authorities to recognize magic mushrooms as a potential therapeutic option. Obtain your psychedelics and shroom delivery from Shroomyz Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Experiences with Psychedelic-Assisted Therapy (PAT) can greatly differ among patients, and it’s crucial to follow specific steps and prepare adequately to ensure a positive result. Patients must go through extensive screening and mental readiness before the substance is consumed.
- Preparation for the Session: Prior to the session, patients undergo a thorough assessment. The therapist will discuss the patient’s goals and expectations to set the right intentions. The therapist will also explain the process and what the patient should expect during the session.
- The Session: A controlled dosage of the substance is administered to patients during the session, which is conducted in a serene, distraction-free environment to promote relaxation and introspection. The therapist offers constant support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps the patient make sense of their experience. Follow-up sessions provide ongoing support and counselling to reinforce the insights and changes achieved during the therapy.
What effect does psilocybin have on the brains of distressed patients?
Psilocybin interacts with the brain by connecting to serotonin receptors, particularly the 5-HT2A receptor. This interaction can result in alterations in perception, mood, and cognition, leading to significant shifts in consciousness, emotional breakthroughs, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients with specific mental health conditions or existential distress are carefully screened to eliminate those with a history of psychosis.
Related Articles:
